Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Novartis currently markets Lutathera (lutetium Lu 177 dotatate), an approved peptide receptor radionuclide therapy (PRRT) for SSTR-positive GEP-NETs. Sanofi has also entered the space, having ...

resulted in longer progression-free survival in patients with extrapancreatic neuroendocrine tumors or pancreatic neuroendocrine tumors that had progressed after previous therapy with Lu-177 ...

and Safety Lutetium Lu 177 dotatate is a radiopharmaceutical therapy approved for the treatment of SSTR-positive GEP-NETs. Due to its radioactive properties, stringent safety protocols are ...

The trial is currently ongoing, and the early findings suggest that the combination therapy is safe, with no new safety concerns identified so far, according to Aman Chauhan, MD. “[Lutetium Lu 177 ...

Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator ... It is administered through intra-arterial hepatic (IAH) injection. It is a radioligand therapy. It was also under ...

Lutetium 177 dotatate showed activity and met the PFS end point in patients ... Currently, there are limited options post surgery and radiation, and systemic therapy remains off-label, with no proven ...

One medicine you might hear about is Lutathera (lutetium lu 177 dotatate). Lutathera was first ... called peptide receptor radionuclide therapy (PRRT). Lutathera works by delivering radiation ...

WASHINGTON — A phase 2 study has demonstrated encouraging results for lutetium-177 ... He added, "Since the dotatate is the same peptide in both imaging and therapy, we can predict prior ...

Use of an approved radionuclide therapy for difficult-to-treat ... treatment with lutetium (Lu)-177 dotatate (Lutathera) was associated with a 6-month PFS rate three times higher than a historical ...